Showing results (291-300 of 793) with videos related to

Sort By:
Pageof 80
Transfusion|May 26, 2012
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphomaJonathan L Kaufman, Christopher R Flowers, Karen D Rados, et al.
Molecular and Cellular Biology|October 5, 2011
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cellsJun Fan, Taro Hitosugi, Tae-Wook Chung, et al.
Cell Reports. Medicine|May 22, 2024
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myelomaMichael Amatangelo, Erin Flynt, Nicholas Stong, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2019
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple MyelomaSundar Jagannath, Leonard T Heffner, Sikander Ailawadhi, et al.
Cancer Cell|September 6, 2007
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathwaySumin Kang, Shaozhong Dong, Ting-Lei Gu, et al.
JCO Oncology Practice|July 7, 2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib InductionLaura F Sun, Kathryn T Maples, Kevin H Hall, et al.
Journal of the Advanced Practitioner in Oncology|October 9, 2023
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple MyelomaRakesh Popat, Sagar Lonial, Peter M Voorhees, et al.
Blood|May 8, 2004
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progressionShaji Kumar, Thomas E Witzig, Michael Timm, et al.
American Journal of Hematology|December 30, 2025
Extramedullary Disease-Achilles Heel in Myeloma?Shaji Kumar, Joshua Richter, Saad Z Usmani, et al.
Targeted Oncology|August 14, 2017
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based AnalysesNeeraj Gupta, Huyuan Yang, Michael J Hanley, et al.
Pageof 80